Insights

Strategic Partnerships Debiopharm has recently formed strategic partnerships with companies such as WhiteLab Genomics, Ubiquigent Limited, and TransCode Therapeutics, indicating potential collaboration opportunities in the pharmaceutical industry.

Targeted Therapeutics The focus on developing targeted nucleic acid therapeutics for cancer suggests a niche market opportunity for personalized medicine solutions, positioning Debiopharm as a key player in advancing innovative treatment options.

Investment in Innovation Debiopharm's investment in Medasystems demonstrates a commitment to accelerating pre-approval treatments, presenting a potential avenue for partnership or investment opportunities in cutting-edge healthcare technologies.

Technology Adoption Utilizing technologies like Kubernetes, Python, and Adobe Creative Suite showcases Debiopharm's tech-forward approach, appealing to tech solution providers looking to collaborate with a forward-thinking pharmaceutical company.

Global Expansion The recent asset sale to Yakult Group highlights Debiopharm's history of global transactions, indicating potential opportunities for expansion or joint ventures in international markets, particularly in the pharmaceutical sector.

Debiopharm Tech Stack

Debiopharm uses 8 technology products and services including Kubernetes, jsDelivr, SAP, and more. Explore Debiopharm's tech stack below.

  • Kubernetes
    Containerization
  • jsDelivr
    Content Delivery Network
  • SAP
    Customer Relationship Management
  • Shopify
    E-commerce
  • MooTools
    Javascript Frameworks
  • jQuery Migrate
    Javascript Libraries
  • Python
    Programming Languages
  • Adobe Creative Suite
    Visualisation Software

Media & News

Debiopharm's Email Address Formats

Debiopharm uses at least 1 format(s):
Debiopharm Email FormatsExamplePercentage
FLast@debiopharm.comJDoe@debiopharm.com
60%
First.Last@debiopharm.comJohn.Doe@debiopharm.com
32%
F.Last@debiopharm.comJ.Doe@debiopharm.com
8%

Frequently Asked Questions

Where is Debiopharm's headquarters located?

Minus sign iconPlus sign icon
Debiopharm's main headquarters is located at Chemin Messidor 5-7 Lausanne, 1006 CH. The company has employees across 3 continents, including EuropeNorth AmericaOceania.

What is Debiopharm's phone number?

Minus sign iconPlus sign icon
You can contact Debiopharm's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Debiopharm's official website and social media links?

Minus sign iconPlus sign icon
Debiopharm's official website is debiopharm.com and has social profiles on LinkedIn.

How much revenue does Debiopharm generate?

Minus sign iconPlus sign icon
As of December 2024, Debiopharm's annual revenue reached $75M.

What is Debiopharm's SIC code NAICS code?

Minus sign iconPlus sign icon
Debiopharm's SIC code is 2833 - Medicinal Chemicals and Botanical Products NAICS code is 334111 - Electronic Computer Manufacturing.

How many employees does Debiopharm have currently?

Minus sign iconPlus sign icon
As of December 2024, Debiopharm has approximately 502 employees across 3 continents, including EuropeNorth AmericaOceania. Key team members include Chief Scientific Officer, Head Of External & Internal Innovation: F. L.Chief Business Officer: N. F.Head Of Digital And It: F. B.. Explore Debiopharm's employee directory with LeadIQ.

What industry does Debiopharm belong to?

Minus sign iconPlus sign icon
Debiopharm operates in the Pharmaceutical Manufacturing industry.

What technology does Debiopharm use?

Minus sign iconPlus sign icon
Debiopharm's tech stack includes KubernetesjsDelivrSAPShopifyMooToolsjQuery MigratePythonAdobe Creative Suite.

What is Debiopharm's email format?

Minus sign iconPlus sign icon
Debiopharm's email format typically follows the pattern of . Find more Debiopharm email formats with LeadIQ.

When was Debiopharm founded?

Minus sign iconPlus sign icon
Debiopharm was founded in 1979.
Debiopharm

Debiopharm

Pharmaceutical ManufacturingLausanne, Switzerland501-1000 Employees

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. 

Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. 

Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat® 

If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!

Section iconCompany Overview

Headquarters
Chemin Messidor 5-7 Lausanne, 1006 CH
Phone number
SIC Code
2833 - Medicinal Chemicals and Botanical Products
NAICS Code
334111 - Electronic Computer Manufacturing
Founded
1979
Employees
501-1000

Section iconFunding & Financials

  • $50M$100M

    Debiopharm's revenue is in the range of $50M$100M

Section iconFunding & Financials

  • $50M$100M

    Debiopharm's revenue is in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.